Bayer: requests EMA to adapt Elyea treatment

(CercleFinance.com) - Bayer announces that it has applied to the European Medicines Agency (EMA) to extend treatment intervals to six months with Eylea 8 mg (aflibercept 8 mg) for two major retinal diseases: age-related macular degeneration (wet AMD) and diabetic macular edema (DME).


This submission is based on positive three-year results from extension studies of the PULSAR and PHOTON clinical trials.

Data show that patients maintained visual and anatomical improvements with a six-month treatment interval.

Eylea 8 mg showed a favourable safety profile, and no new alerts were detected.


Copyright (c) 2025 CercleFinance.com. All rights reserved.